These are based on promising results from animal experiments, where markedly improved outcomes have been noted (for example, in sepsis, burn [24] brain inflammation [25] and diabetes in mice [23] and rats) after exogenous administration of gelsolin, thereby advocating a need for the “gelsolin replacement therapy”. This evidence concerns the gene GSN and Sepsis.